✦ LIBER ✦

Fatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantation

✍ Scribed by Daniele Focosi; Elisabetta Sordi; Federico Papineschi; Edoardo Benedetti; Sara Galimberti; Mario Petrini

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 87 KB
Volume: 81
Category: Article
ISSN: 0146-6615
DOI: 10.1002/jmv.21440

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Human cytomegalovirus (HCMV) reactivation can cause a wide range of complications in hematopoietic stem cell transplant recipients, ranging from pneumonia to graft failure. Although reactivations are usually seen in the early post‐transplant period, ongoing and untreated HCMV reactivation at the time of high‐dose chemotherapy and autologous stem cell support is an exceedingly rare circumstance whose consequences remain largely unknown. This case report describes a patient who underwent high‐dose melphalan and autologous transplantation with unknown active HCMV replication. J. Med. Virol. 81:857–860, 2009. © 2009 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Primary AL amyloid polyneuropathy succes

Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation

✍ Nagaaki Katoh; Masayuki Matsuda; Takuhiro Yoshida; Masahide Yazaki; Hiroshi Mori 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

## Abstract We report 2 patients with polyneuropathy associated with amyloid derived from light chains (AL) who were treated successfully with high‐dose melphalan followed by autologous peripheral blood stem cell transplantation (HDM/SCT). Neuropathic symptoms improved in conjunction with normaliza

Thrombotic microangiopathy (TMA) and str

Thrombotic microangiopathy (TMA) and stroke due to human herpesvirus-6 (HHV-6) reactivation in an adult receiving high-dose melphalan with autologous peripheral stem cell transplantation

✍ Amy Belford; Otha Myles; Alan Magill; James Wang; Rick C. Myhand; Jamie K. Wasel 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB

Autologous peripheral stem cell transpla

Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan

✍ Ursula A. Matulonis; James D. Griffin; Dr. George P. Canellos 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 2 views

Post-transplant outcomes of induction th

Post-transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support

✍ Dan T. Vogl; Stephen V. Liu; Elise A. Chong; Selina M. Luger; David L. Porter; S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 2 views

High dose therapy and autologous stem ce

High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy

✍ Arturo Molina; Amrita Y. Krishnan; Auayporn Nademanee; Rachel Zabner; Irena Snie 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame